83 related articles for article (PubMed ID: 22138003)
1. Health economics of screening for gynaecological cancers.
Kulasingam S; Havrilesky L
Best Pract Res Clin Obstet Gynaecol; 2012 Apr; 26(2):163-73. PubMed ID: 22138003
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness analysis of HPV vaccination alongside cervical cancer screening programme in Slovenia.
Obradovic M; Mrhar A; Kos M
Eur J Public Health; 2010 Aug; 20(4):415-21. PubMed ID: 20624834
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of primary HPV screening for cervical cancer in Germany--a decision analysis.
Sroczynski G; Schnell-Inderst P; Mühlberger N; Lang K; Aidelsburger P; Wasem J; Mittendorf T; Engel J; Hillemanns P; Petry KU; Krämer A; Siebert U
Eur J Cancer; 2011 Jul; 47(11):1633-46. PubMed ID: 21482103
[TBL] [Abstract][Full Text] [Related]
5. Introducing HPV vaccine and scaling up screening procedures to prevent deaths from cervical cancer in Japan: a cost-effectiveness analysis.
Yamamoto N; Mori R; Jacklin P; Osuga Y; Kawana K; Shibuya K; Taketani Y
BJOG; 2012 Jan; 119(2):177-86. PubMed ID: 21794070
[TBL] [Abstract][Full Text] [Related]
6. Screening, prevention and treatment of cervical cancer -- a global and regional generalized cost-effectiveness analysis.
Ginsberg GM; Edejer TT; Lauer JA; Sepulveda C
Vaccine; 2009 Oct; 27(43):6060-79. PubMed ID: 19647813
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
de Kok IM; van Ballegooijen M; Habbema JD
J Natl Cancer Inst; 2009 Aug; 101(15):1083-92. PubMed ID: 19571256
[TBL] [Abstract][Full Text] [Related]
8. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of cervical cancer prevention.
Esselen KM; Feldman S
Clin Obstet Gynecol; 2013 Mar; 56(1):55-64. PubMed ID: 23318570
[TBL] [Abstract][Full Text] [Related]
10. The health and economic impact of cervical cancer screening and human papillomavirus vaccination in kidney transplant recipients.
Wong G; Howard K; Webster A; Chapman JR; Craig JC
Transplantation; 2009 Apr; 87(7):1078-91. PubMed ID: 19352131
[TBL] [Abstract][Full Text] [Related]
11. Promising strategies for cervical cancer screening in the post-human papillomavirus vaccination era.
Tota J; Mahmud SM; Ferenczy A; Coutlée F; Franco EL
Sex Health; 2010 Sep; 7(3):376-82. PubMed ID: 20719230
[TBL] [Abstract][Full Text] [Related]
12. Modeling cost-effectiveness of cervical cancer screening in Hungary.
Vokó Z; Nagyjánosi L; Margitai B; Kövi R; Tóth Z; László D; Kaló Z
Value Health; 2012 Jan; 15(1):39-45. PubMed ID: 22264970
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: adaptation of an existing cohort model to the situation in the Netherlands.
Rogoza RM; Westra TA; Ferko N; Tamminga JJ; Drummond MF; Daemen T; Wilschut JC; Postma MJ
Vaccine; 2009 Jul; 27(35):4776-83. PubMed ID: 19539578
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
[TBL] [Abstract][Full Text] [Related]
15. A cost-utility analysis of adding a bivalent or quadrivalent HPV vaccine to the Irish cervical screening programme.
Dee A; Howell F
Eur J Public Health; 2010 Apr; 20(2):213-9. PubMed ID: 19864366
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of cervical-cancer screening in five developing countries.
Goldie SJ; Gaffikin L; Goldhaber-Fiebert JD; Gordillo-Tobar A; Levin C; Mahé C; Wright TC;
N Engl J Med; 2005 Nov; 353(20):2158-68. PubMed ID: 16291985
[TBL] [Abstract][Full Text] [Related]
17. [Is early cervical cancer screening justified?].
Baldauf JJ; Fender M; Akladios CY; Velten M
Gynecol Obstet Fertil; 2011 Jun; 39(6):358-63. PubMed ID: 21600827
[TBL] [Abstract][Full Text] [Related]
18. Preventing cervical cancer : overviews of the National Breast and Cervical Cancer Early Detection Program and 2 US immunization programs.
Khan K; Curtis CR; Ekwueme DU; Stokley S; Walker C; Roland K; Benard V; Saraiya M
Cancer; 2008 Nov; 113(10 Suppl):3004-12. PubMed ID: 18980296
[TBL] [Abstract][Full Text] [Related]
19. [Cost effectiveness of human papilloma virus testing in cervical cancer screening: a literature review].
Mejía A; Salas W
Biomedica; 2008 Mar; 28(1):160-72. PubMed ID: 18645671
[TBL] [Abstract][Full Text] [Related]
20. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands.
Coupé VM; de Melker HE; Snijders PJ; Meijer CJ; Berkhof J
Vaccine; 2009 Aug; 27(37):5111-9. PubMed ID: 19567242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]